(Q57697052)

1

0 references

Steven J Romano

2

0 references

Susan Babcock

3

0 references

Julia Dillon

4

0 references

Cathy Shuler

5

0 references

Charlene Berger

6

0 references

Diana Carter

7

0 references

Robert Reid

8

0 references

Susanne Steinberg

10

0 references

Rajinder Judge

British Journal of Obstetrics and Gynaecology

11

0 references

publication date

May 2001

0 references

published in

0 references

volume

108

0 references

issue

5

0 references

page(s)

462-468

0 references

cites work

The epidemiology and social impact of premenstrual symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Late luteal phase dysphoric disorder in young women

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Effect of clomipramine on premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Paroxetine as a treatment for premenstrual dysphoric disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Fluoxetine in the treatment of premenstrual dysphoria

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

The measurement of premenstrual mood symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Prospective assessment of menstrually related mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Clinical applications of visual analogue scales: a critical review.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Premenstrual syndrome: documentation by a linear analog scale compared with two descriptive scales

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Fluoxetine in the treatment of premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

The role of serotonin in premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Therapeutic effect of sleep deprivation in patients with premenstrual syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Morning versus evening bright light treatment of late luteal phase dysphoric disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Allopregnanolone concentrations and premenstrual syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Progesterone metabolite allopregnanolone in women with premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA(A) receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021

Estrogen increases the density of 5-hydroxytryptamine(2A) receptors in cerebral cortex and nucleus accumbens in the female rat

1 reference

https://api.crossref.org/works/10.1016%2FS0306-5456%2800%2900120-0

7 January 2021